<DOC>
	<DOCNO>NCT00908596</DOCNO>
	<brief_summary>Patients moderate severe renal impairment schedule magnetic resonance imaging ( MRI ) scan injection contrast agent , Primovist/Eovist , ask participate . The administration contrast agent contain gadolinium Primovist/Eovist might increase potential risk develop rare condition call nephrogenic systemic fibrosis ( NSF ) patient renal impairment . This study assess potential risk develop NSF patient renal impairment administration Primovist/Eovist . Patients enrol study receive Primovist/Eovist enhance MRI scan prescribe refer doctor . After MRI scan patient include two year follow-up period ass sign symptom suggestive NSF appear .</brief_summary>
	<brief_title>Primovist / Eovist Renally Impaired Patients</brief_title>
	<detailed_description>Adverse event data report Adverse Events section .</detailed_description>
	<mesh_term>Nephrogenic Fibrosing Dermopathy</mesh_term>
	<criteria>Patient must schedule Contrast enhance magnetic resonance imaging ( CEMRI ) liver Primovist/Eovist base careful risk/benefit evaluation recommend dose one approve indication Patient must fulfill criterion moderate ( Estimated glomerular filtration rate [ eGFR ] 30 59 mL/min/1.73 m^2 ) severe ( eGFR &lt; 30 mL/min/1.73 m^2 ) renal impairment . Gadolinium base contrast agent ( GBCA ) enhance MRI ( administration GBCA CE image procedure ) Primovist/Eovist within 12 month prior administration Primovist/Eovist History exist NSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Nephrogenic Systemic Fibrosis ( NSF )</keyword>
	<keyword>Primovist / Eovist</keyword>
</DOC>